var data={"title":"Pathogenesis of Beh√ßet syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathogenesis of Beh&ccedil;et syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/contributors\" class=\"contributor contributor_credentials\">Ellison L Smith, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/contributors\" class=\"contributor contributor_credentials\">Yusuf Yazici, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/contributors\" class=\"contributor contributor_credentials\">Peter A Merkel, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/contributors\" class=\"contributor contributor_credentials\">Monica Ramirez Curtis, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 17, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beh&ccedil;et syndrome, also known as Beh&ccedil;et disease, is an inflammatory disease characterized by recurrent oral aphthous ulcers and numerous potential systemic manifestations. These include genital ulcers; skin lesions; and ocular, neurologic, vascular, articular, and gastrointestinal disease.</p><p>Many, but not all, clinical manifestations of Beh&ccedil;et syndrome are believed to be due to vasculitis. Among the systemic vasculitides, Beh&ccedil;et syndrome is remarkable for its ability to involve blood vessels of all sizes (small, medium, and large) on both the arterial and venous sides of the circulation.</p><p>The etiology and pathogenesis of Beh&ccedil;et syndrome are discussed in this review. The clinical manifestations, diagnosis, and treatment of this disorder are presented separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-behcet-syndrome\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Beh&ccedil;et syndrome&quot;</a> and <a href=\"topic.htm?path=treatment-of-behcet-syndrome\" class=\"medical medical_review\">&quot;Treatment of Beh&ccedil;et syndrome&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Beh&ccedil;et syndrome is more common (and often more severe) along the ancient silk road, which extends from eastern Asia to the Mediterranean [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. It is most common in Turkey (80 to 370 cases per 100,000), while the prevalence ranges from 13.5 to 20 per 100,000 in Japan, Korea, China, Iran, and Saudi Arabia [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. Prevalence in Paris, France in 2003 was 7.1 per 100,000, with rates of 2.4 per 100,000 in those of European ancestry, of 34.6 per 100,000 in those of North African ancestry, and of 17.5 per 100,000 in those of Asian ancestry [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/2,3\" class=\"abstract_t\">2,3</a>]. Estimates of prevalence in the United States and Europe have ranged from 0.12 to 7.5 per 100,000. Analysis of residents of Olmsted County, Minnesota over a 45-year period identified a prevalence of 5.2 per 100,000 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. It is somewhat more common in men in the eastern Mediterranean area and in women in north European countries, and it typically affects young adults 20 to 40 years of age [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. Immigrant and refugee populations from areas of high Beh&ccedil;et syndrome prevalence demonstrate increased risk of disease development [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The underlying cause of Beh&ccedil;et syndrome is unknown. As with other autoimmune diseases, the disorder may represent aberrant immune activity triggered by exposure to an agent, perhaps infectious, in patients with a genetic predisposition to develop the disease. Major disease mechanisms in Beh&ccedil;et syndrome include the following [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/6\" class=\"abstract_t\">6</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Genetic influences, including association with certain human leukocyte antigens (HLA) as well as some non-HLA genes</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered host bacteria or bacteria response</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered populations of hematopoietic cells and associated cytokines</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of immune complexes and autoantibodies</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vascular endothelial activation and hypercoagulability</p><p/><p>Proposed triggering agents include viral and bacterial antigens or other environmental sources, such as chemicals or heavy metals. Direct infection of affected tissues has not been observed, although it is still a possible contributor.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Genetic</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic predisposition to the disease is likely polygenic.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">HLA genes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Increased risk of developing Beh&ccedil;et syndrome is associated with the presence of certain human leukocyte antigens, particularly HLA-B51. A meta-analysis of 4800 cases and 16,289 controls has shown a significant increase in the risk of <span class=\"nowrap\">HLA-B51/B5</span> carriers to develop Beh&ccedil;et syndrome compared with non-carriers (pooled odds ratio of 5.8) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/7\" class=\"abstract_t\">7</a>]. This relationship was consistent across multiple geographic locations, including Eastern Asia, Middle <span class=\"nowrap\">East/North</span> Africa, Southern Europe, and <span class=\"nowrap\">Northern/Eastern</span> Europe, but insufficient data were available for analysis of North American studies.</p><p>In individual studies, higher than baseline prevalences of HLA-B51 has been found in Beh&ccedil;et syndrome patients in Italy (odds ratio of 5.9), in Germany, and in Middle Eastern and Far Eastern countries along the silk road (63 versus 9 percent in controls), of HLA-B52 (21 versus 9 percent) in Israel, and of HLA-B57 in the United Kingdom [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/1,8-13\" class=\"abstract_t\">1,8-13</a>]. HLA-B5101 and, to a lesser extent, HLA-5108 alleles have been most closely linked in patients along the Silk Road [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. Other HLA alleles may increase (HLA-B15, HLA-B27, HLA-B57, HLA-26) or decrease (HLA-B49, HLA-A03) the risk for Beh&ccedil;et syndrome in various populations and in men and women [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/15-18\" class=\"abstract_t\">15-18</a>]. However, the HLA contribution was estimated to be less than 20 percent in one study [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/19\" class=\"abstract_t\">19</a>].</p><p>There may also be a genetic contribution to disease severity. Presence of a HLA-B51 allele has been associated with worse disease in several studies [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/1,20-23\" class=\"abstract_t\">1,20-23</a>].</p><p>Several possible mechanisms for the genetic linkage to HLA-B51 have been suggested:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alterations in the B pocket of the antigen-binding groove conformed by HLA-B51 may determine whether Beh&ccedil;et syndrome associated peptides bind and contribute to Beh&ccedil;et syndrome activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/24,25\" class=\"abstract_t\">24,25</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cross-reactivity between HLA-B51 and organ-specific antigens may exist [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Linkage disequilibrium with other disease-associated genes has been reported on chromosome 6, including a tumor necrosis factor (TNF) promoter polymorphism in proximity to the HLA B gene locus, to the MICA gene (major histocompatibility complex class I chain-related gene A), and a locus telomeric to the HLA-B site, and other nearby loci [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/11,13,27-32\" class=\"abstract_t\">11,13,27-32</a>].</p><p/><p>Though most cases of Beh&ccedil;et syndrome are sporadic, families with multiple affected members, known as familial clustering, have been reported, and having a first-degree relative with Beh&ccedil;et syndrome does increase risk for the disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/33,34\" class=\"abstract_t\">33,34</a>]. HLA-B51 rates are higher in familial than in sporadic cases. Affected children of patients with Beh&ccedil;et syndrome may have an earlier age of onset, a property termed genetic anticipation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/35\" class=\"abstract_t\">35</a>]; this characteristic has been linked, in many genetic disorders, to an increased number of nucleotide repeats within each successive generation. In Beh&ccedil;et syndrome, for example, a triplet repeat microsatellite polymorphism of (GCT)n found within a major histocompatibility complex (MHC) Class I related gene was found to be associated with the disorder in one study of 77 affected patients in Japan [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/36\" class=\"abstract_t\">36</a>].</p><p>Several meta-analyses have demonstrated that the major histocompatibility complex class I chain related gene A (MICA) A6 allele is associated with increased susceptibility to Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/37-39\" class=\"abstract_t\">37-39</a>].</p><p>HLA-B51 positivity is associated in Beh&ccedil;et syndrome patients with HAP10, a low activity variant of endoplasmic reticulum aminopeptidase 1 (ERAP1). Cellular studies with HAP10 have demonstrated the production of longer peptides, with resultant changes to the peptidome, which may act to stimulate immune activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Polymorphisms of the ERAP1 gene have been described in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/42,43\" class=\"abstract_t\">42,43</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Non-HLA genes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Non-HLA genes also play a role in determining susceptibility to disease. Genome-wide screening of affected families with more than one affected member has identified additional, non-HLA regions of potential interest [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/44\" class=\"abstract_t\">44</a>]. Examples include associations between Beh&ccedil;et syndrome and:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polymorphisms of the intercellular adhesion molecule (ICAM)-1 gene, the endothelial nitric oxide synthase gene, TNF genes, the vascular endothelial growth factor (VEGF) gene, manganese superoxide dismutase gene, cytochrome P450 gene, the interleukin (IL)-10 gene, the IL-23 receptor gene, and many other genes [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/11,20,45-67\" class=\"abstract_t\">11,20,45-67</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Missense mutations of the familial Mediterranean fever (MEFV) gene, encoding the protein pyrin that is expressed of the surface of neutrophils [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/68-71\" class=\"abstract_t\">68-71</a>]</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Altered bacteria and bacteria response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Altered host bacteria or response to bacteria may play a role in the pathogenesis of Beh&ccedil;et syndrome.</p><p>Molecular mimicry may play a role, and studies suggest a possible pathogenic role of certain bacterial antigens that have cross-reactivity with human peptides. The cross-reactive self-antigens may include the heat shock proteins, a family of 60 to 90 kDa proteins produced by many cells in response to stress. These proteins have significant sequence homology between humans and bacteria. T cells <span class=\"nowrap\">and/or</span> antibodies may recognize epitopes shared by both host and infectious organism heat shock proteins, thereby initiating <span class=\"nowrap\">and/or</span> perpetuating Beh&ccedil;et syndrome.</p><p>Elevated levels of antibodies against epitopes of mycobacterial heat shock protein, some of which have significant homology to human heat shock proteins, have been observed among patients with Beh&ccedil;et syndrome. One study evaluated the antigenicity of 47 synthetic peptides (each 15 amino acids in length) derived from the sequence of the mycobacterial 65 kD heat shock protein [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/72\" class=\"abstract_t\">72</a>]. Increased levels of IgG and IgA antibodies against three of these synthetic peptides was observed, two of which had significant homology to two areas of a human mitochondrial 60 kD heat shock protein. Exacerbations of ocular disease coincided with enhanced levels of these autoimmune antibodies [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/73\" class=\"abstract_t\">73</a>]. Furthermore, these peptides can induce uveitis when injected into Lewis rats.</p><p>A response to mycobacterial heat shock proteins by gamma-delta T cells may play a role in the pathogenesis of Beh&ccedil;et syndrome. One study found that 25 of 33 patients with Beh&ccedil;et syndrome showed significant increases in gamma-delta T cells in response to exposure to mycobacterial heat shock proteins; by comparison, only 2 of 55 control individuals exhibited such an increase [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/74\" class=\"abstract_t\">74</a>].</p><p>Specific bacteria, particularly streptococci, may also be important contributors to the immune response among patients with Beh&ccedil;et syndrome:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skin testing to streptococcal antigens often induces hypersensitivity reactions and sometimes results in systemic exacerbations of Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/75\" class=\"abstract_t\">75</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A study of 106 Beh&ccedil;et syndrome patients from Turkey showed a higher rate of <em>Streptococcal mutans</em> salivary colonization compared with controls, and colonization was associated with low levels of serum mannose-binding lectin compared with controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/76\" class=\"abstract_t\">76</a>]. Another study of 54 Beh&ccedil;et syndrome patients compared with 25 healthy controls and 8 patients with recurrent aphthous stomatitis found variations in oral mucosal and salivary microbial communities between the groups [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/77\" class=\"abstract_t\">77</a>]. An evaluation of the fecal microbiota of 22 Beh&ccedil;et syndrome patients compared with 16 healthy cohabitating controls found significant differences in the microbiome signature of the Beh&ccedil;et syndrome patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/78\" class=\"abstract_t\">78</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Indirect evidence for cross-reactivity is suggested by the finding that patients with Beh&ccedil;et syndrome are more likely than normals to have significant antibody titers to <em>Streptococcus sanguis</em> [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/79,80\" class=\"abstract_t\">79,80</a>]; this organism, particularly some with uncommon serotypes, is found at increased levels in the oral cavities of patients with the disorder. Circulating antibodies have been detected to streptococcal heat shock proteins [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/81\" class=\"abstract_t\">81</a>]. Patients with Beh&ccedil;et syndrome demonstrate increased reactivity to lipoteichoic acid, a streptococcal antigen.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Streptococcal antigens have been shown to increase IL-6 and interferon gamma secretion from Beh&ccedil;et syndrome patients' T lymphocytes and to upregulate Beh&ccedil;et syndrome patients' gamma delta T cells, which secrete IL-6, IL-8 and TNF-alpha [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/82-84\" class=\"abstract_t\">82-84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The importance of streptococcal infection was indirectly assessed by a prospective study which compared the efficacy of benzathine G penicillin plus <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">colchicine</a> in 94 patients with Beh&ccedil;et syndrome with that of colchicine alone in 60 patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/85\" class=\"abstract_t\">85</a>]. Compared with colchicine alone, penicillin plus colchicine resulted in a significantly greater degree of improvement in mucocutaneous lesions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Host response to <em>Helicobacter pylori</em> infection may play a role. This was illustrated in a study that found similar rates of serum <em>Helicobacter pylori</em> IgG levels between patients and controls but found a higher rate of <em>Helicobacter pylori</em> cytotoxin-associated gene-A antibodies in Beh&ccedil;et patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/86\" class=\"abstract_t\">86</a>]. These antibodies have been postulated to be mediators of vascular damage in other conditions via cross-reaction with endothelin antigens. <em>Helicobacter</em> eradication in these patients decreased Beh&ccedil;et syndrome activity.</p><p/><p>Herpes simplex virus (HSV) has been investigated as a possible infectious trigger in Beh&ccedil;et syndrome. HSV type-1 genome has been isolated from the nuclei of lymphocytes in Beh&ccedil;et syndrome patients, and immune complexes containing HSV-1 antigen have been reported. Other studies have not shown an association between HSV and Beh&ccedil;et syndrome, including polymerase chain reaction (PCR) testing of saliva and a randomized trial of <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> treatment that was not effective [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Parvovirus B19 was the subject of an investigation that used a semiquantitative technique to assess the amount of parvovirus B19 DNA present in 40 patients and controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/12\" class=\"abstract_t\">12</a>]. There was more B19 DNA present in the nonulcerative skin lesions of Beh&ccedil;et syndrome patients than in the ulcerative skin lesions or in control patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Altered innate immune function</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mannose-binding lectin (MBL) is part of the innate immune system and activates the complement cascade after binding to carbohydrate structures on microorganisms. Low serum levels of MBL and MBL gene mutations have been observed in Beh&ccedil;et syndrome as well as in other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Very low levels of MBL correlated with increased disease severity. Since MBL deficiencies are associated with increased risk of some infections, and since infectious disease has been associated with Beh&ccedil;et syndrome, MBL deficiencies may lead to impaired immune response against microorganisms and subsequent immune activation in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/76,87\" class=\"abstract_t\">76,87</a>].</p><p>Toll-like receptors are receptors on lymphocytes and some solid tissue cells which are directed against pathogenic microbes and which are a part of the innate immune system. Altered patterns of toll-like receptors have been described in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/88-90\" class=\"abstract_t\">88-90</a>]. Monocytes of Beh&ccedil;et syndrome patients with active disease demonstrate increased activity of toll-like receptors 2 and 4, and, in one study, this was inversely correlated with 25-OH vitamin D levels [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/91,92\" class=\"abstract_t\">91,92</a>]. Intestinal lesions in Beh&ccedil;et syndrome patients expressed increased toll-like receptor 2 and 4 mRNA compared with healthy controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/93\" class=\"abstract_t\">93</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Cellular immunity and cytokines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In Beh&ccedil;et syndrome, there are alterations in the numbers of T cell subpopulations and evidence of cellular activation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. Autoreactive T cells appear to play a critical role in the pathogenesis of Beh&ccedil;et syndrome, and a trial of lymphocyte depletion with an anti-CD52 monoclonal antibody CAMPATH-1H appeared to reduce disease activity in 18 patients with Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/94\" class=\"abstract_t\">94</a>]. As noted above, heat shock proteins or streptococcal antigens may play a role in stimulating oligoclonal T cell expansion [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/74\" class=\"abstract_t\">74</a>]. Adenosine deaminase, an enzyme involved in lymphocyte proliferation, maturation, and differentiation, is activated in Beh&ccedil;et syndrome, particularly during disease exacerbations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/95-97\" class=\"abstract_t\">95-97</a>].</p><p>A T helper (Th) 1 predominant response has been observed in many studies of Beh&ccedil;et syndrome, but some studies have shown evidence for a Th2 response. In reality there may be a mix of Th1 and Th2 activity in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,98-100\" class=\"abstract_t\">14,98-100</a>].</p><p>Th1 lymphocytes, which produce cytokines IL-2, IL-6, IL-8, IL-12, IL-18, TNF-alpha, and interferon gamma, are increased in many studies in patients with Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,98,101-107\" class=\"abstract_t\">14,98,101-107</a>]. Some studies have shown that serum levels of IL-12, soluble TNF-alpha receptors, and IL-8 may correlate with disease activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/108-112\" class=\"abstract_t\">108-112</a>], while others have noted increased production of such cytokines from peripheral blood mononuclear cells of Beh&ccedil;et syndrome patients regardless of disease activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/113\" class=\"abstract_t\">113</a>]. Twenty-four patients with active ocular Beh&ccedil;et syndrome demonstrated elevated levels of IgA, C3, C4, IL-6, IL-8, and TNF-alpha compared with controls; a study of 43 patients with active versus inactive Beh&ccedil;et posterior uveitis showed activity correlated with increased serum levels of IL-6, IL-8, TNF-alpha, VEGF, and malondialdehyde (MDA) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/105,114\" class=\"abstract_t\">105,114</a>]. Elevated cerebrospinal fluid IL-6 levels have been observed in Beh&ccedil;et syndrome patients with active neurologic disease and may be a marker of disease activity and persistence [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/115\" class=\"abstract_t\">115</a>]. Increased IL-8, monocyte chemoattractant protein 1, interferon-gamma, and IL-12 messenger RNA were observed in biopsy specimens from 20 patients with active Beh&ccedil;et syndrome compared with healthy controls; no increase in IL-4 and IL-13 was observed in this study [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/104\" class=\"abstract_t\">104</a>]. Increased expression of IL-23 mRNA has been described in Beh&ccedil;et erythema nodosum-like lesions [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/116\" class=\"abstract_t\">116</a>]. It has been suggested that plasmacytoid dendritic cells and type I interferons play a role in polarizing the immune activity toward Th1 activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/117\" class=\"abstract_t\">117</a>].</p><p>Th2 phenotype associated changes have also been observed. Studies have shown peripheral blood mononuclear cells from patients with Beh&ccedil;et syndrome produce increased amounts of IL-4, IL-10, and IL-13 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/33,99,118\" class=\"abstract_t\">33,99,118</a>]. Analysis of T cell subpopulations in patients with Beh&ccedil;et syndrome has shown relative increases in the CD8:CD4 ratio, with relative reductions in percentages of suppressor T cells, particularly in patients with active disease. Levels of serum soluble CD30, which is released from CD4+ Th2 cells and which is a marker of TH2 activity, is elevated in Beh&ccedil;et syndrome patients with active disease. Others have suggested that Th1 and Th17 may be involved in the disease's active phases, while Th2 may have an impact on disease course and severity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/119\" class=\"abstract_t\">119</a>].</p><p>T helper 17 (Th17) cells, which produce IL-17 and which are distinct from Th1 and Th2 lymphocytes, have been found to be increased and activated in patients with Beh&ccedil;et syndrome and may explain some of the apparently conflicting findings regarding Th1 and Th2 activity in this disorder [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/120-128\" class=\"abstract_t\">120-128</a>].</p><p>Changes in T cell subsets have been identified in a number of studies, including increased numbers of T cells carrying the activation markers CD29 and CD69 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,129-132\" class=\"abstract_t\">14,129-132</a>]. Patients with Beh&ccedil;et syndrome have relatively high levels of gamma-delta T cells in the circulation and at inflammatory sites [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/72,74,129,133,134\" class=\"abstract_t\">72,74,129,133,134</a>]; such cells are also present in peripheral blood in higher numbers during active versus quiescent Beh&ccedil;et syndrome (9 versus 2 percent, respectively) [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/133\" class=\"abstract_t\">133</a>]. Gamma-delta T cell activation may be polyclonal; the response may be to a variety of antigenic stimuli [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/135\" class=\"abstract_t\">135</a>]. Soluble CD28, which may play a role in T cell regulation, is elevated in the serum of patients with active Beh&ccedil;et syndrome, levels may correlate with disease activity, and polymorphisms of CD28 and CTLA-4 (which binds CD28) have been associated with Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/43,61,136\" class=\"abstract_t\">43,61,136</a>]. HLA-B51 restricted CD8+ cytotoxic T lymphocytes autoreactive to MHC class I chain related gene A (MICA), a protein preferentially expressed on epithelial and endothelial cells in a stress-dependent manner, have been described in Beh&ccedil;et syndrome patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/137\" class=\"abstract_t\">137</a>].</p><p>Flow cytometric analysis of immune cells from the aqueous humor of patients with active Beh&ccedil;et uveitis showed elevated levels of CD8+ T cells and CD3+CD56+ NK T cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/138\" class=\"abstract_t\">138</a>]. Other studies have also shown T lymphocyte infiltration into the eye in Beh&ccedil;et syndrome by CD4+ Th1 cells [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/139-141\" class=\"abstract_t\">139-141</a>]. Th1 cytokines are elevated in the aqueous humor and serum of patients with Beh&ccedil;et uveitis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/142,143\" class=\"abstract_t\">142,143</a>]. Ocular fluid from Beh&ccedil;et syndrome patients with active uveitis demonstrated inflammatory cytokines, including interferon, IL-2, TNF, IL-6, and IL-17, and activated ocular CD4+ T cells produced large amounts of TNF and IL-17, which were blocked in the presence of the TNF inhibitor <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a> [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/120\" class=\"abstract_t\">120</a>].</p><p>Synovial fluid in Beh&ccedil;et syndrome demonstrates lower levels of inflammatory cytokines than that in patients with rheumatoid arthritis, a more erosive disease. One study showed elevated levels of IL-8 and soluble IL-2 receptor but relatively lower levels of TNF-alpha, IL-1 beta, IL-1 receptor antagonist, and transforming growth factor (TGF) beta than the synovial fluid from patients with rheumatoid arthritis. Another study showed elevated levels of IL-1 beta but lower levels of IL-18, TNF-alpha, and matrix metalloproteinase (MMP)-3 compared with rheumatoid arthritis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/144\" class=\"abstract_t\">144</a>]. Bronchoalveolar lavage from patients with Beh&ccedil;et pulmonary disease shows higher levels of IL-18 and interferon-gamma before and after LPS stimulation than in controls.</p><p>The inflammatory response in Beh&ccedil;et syndrome may be accentuated by refractoriness of activated T cells and neutrophils to apoptosis. T cells from patients with Beh&ccedil;et syndrome demonstrate resistance to spontaneous and CD95-induced apoptosis, and this may be mediated by NF-kappaB via regulation of apoptosis-related factors and death receptors [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/145\" class=\"abstract_t\">145</a>]. Circulating neutrophils are resistant to apoptosis in the remission stage of Beh&ccedil;et uveitis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/146\" class=\"abstract_t\">146</a>].</p><p>Neopterin is secreted by monocytes and macrophages as a result of interferon-gamma secretion by activated T lymphocytes and may, therefore, be an indicator of cellular immune activation. Elevated serum and urine neopterin levels have been observed in Beh&ccedil;et syndrome patients compared with controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/147,148\" class=\"abstract_t\">147,148</a>].</p><p>Alterations in cellular signaling pathways in Beh&ccedil;et syndrome has been described. One study showed activation of the <span class=\"nowrap\">JAK1/STAT3</span> pathway in CD14(+) monocytes and CD4(+) T cells in nine Beh&ccedil;et syndrome patients compared with nine healthy controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/149\" class=\"abstract_t\">149</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Autoantibody and immune complex formation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to cellular immune activation, there is also evidence of humoral immune activation in Beh&ccedil;et syndrome. Increased numbers of circulating B lymphocytes have been observed; this appears to be antigen driven, not simply a polyclonal increase [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,150,151\" class=\"abstract_t\">14,150,151</a>].</p><p>Autoantibodies appear to play a role in the pathogenesis of Beh&ccedil;et syndrome. Autoantibodies have been described against a number of targets including oral mucosal antigens, endothelial cells, T cell costimulatory molecule CTLA-4, killer immunoglobulin-like receptors, oxidized low-density lipoprotein, and kinectin [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/152-157\" class=\"abstract_t\">152-157</a>]. Anti-saccharomyces cerevisiae antibodies (ASCA) have been observed in some Beh&ccedil;et syndrome patients, at rates similar to that in ulcerative colitis and ankylosing spondylitis and less commonly than in Crohn disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/158\" class=\"abstract_t\">158</a>].</p><p>Autoimmune activity against retinal self-antigens appears to be important in the pathogenesis of Beh&ccedil;et uveitis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/159\" class=\"abstract_t\">159</a>]. Retinal-S antigen is localized to the photoreceptor of the retina, and has been shown to be a potent uveitic autoantigen [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/160\" class=\"abstract_t\">160</a>]. Peripheral blood S-antigen responsive lymphocytes are elevated during exacerbations of ocular inflammation in Beh&ccedil;et syndrome patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/161,162\" class=\"abstract_t\">161,162</a>]. Other suspected Beh&ccedil;et syndrome retinal autoantigens are alpha tropomyosin, <a href=\"topic.htm?path=selenium-drug-information\" class=\"drug drug_general\">selenium</a> binding protein, and interphotoreceptor retinoid binding protein [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/163-165\" class=\"abstract_t\">163-165</a>]. Alpha-tropomyosin or kinectin is a membrane protein predominantly confined to the endoplasmic reticulum [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/163,166,167\" class=\"abstract_t\">163,166,167</a>]. Immunization of rodents with alpha-tropomyosin can cause inflammation of the uveal tract and the skin, reminiscent of lesions seen in Beh&ccedil;et syndrome. Antikinectin antibodies are present at modestly higher rates and titers in Beh&ccedil;et syndrome patients than in patients with other autoimmune connective tissue diseases [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/157\" class=\"abstract_t\">157</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Endothelial activation and altered coagulation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Endothelial dysfunction is a characteristic finding in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/168\" class=\"abstract_t\">168</a>]. Endothelium-dependent flow-mediated dilation is reduced [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/169,170\" class=\"abstract_t\">169,170</a>]. Endothelial activation in affected blood vessels is a mediator of vascular inflammation as well as thrombosis in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/152,153,171,172\" class=\"abstract_t\">152,153,171,172</a>].</p><p>A number of molecules have been identified that interact to mediate endothelial dysfunction in Beh&ccedil;et syndrome. Nitric oxide (NO) is a highly reactive molecule associated with inflammatory activity and endothelial function. A number of lines of research have documented the role of NO in endothelial activation in Beh&ccedil;et syndrome, including increased serum, erythrocyte, synovial, and aqueous humor NO concentrations in Beh&ccedil;et syndrome, and elevated levels of NO metabolites compared with controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/153,173-177\" class=\"abstract_t\">153,173-177</a>]. Polymorphisms of endothelial NO synthase genes and related genes have been associated with susceptibility to Beh&ccedil;et syndrome in some populations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/42,45,47,51\" class=\"abstract_t\">42,45,47,51</a>]. Elevated levels of symmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, have been observed in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/178\" class=\"abstract_t\">178</a>].</p><p>Increased oxidative stress has been observed in patients with Beh&ccedil;et syndrome. Findings have included increased plasma MDA, reduced glutathione:oxidized glutathione ratio, reduced superoxide dismutase, and elevated catalase [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/169,179\" class=\"abstract_t\">169,179</a>].</p><p>Elevated mean plasma homocysteine levels have been observed in Beh&ccedil;et syndrome, and this has been found to be associated with NO concentrations and decreased flow-mediated vessel dilatation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/180,181\" class=\"abstract_t\">180,181</a>]. A number of studies have shown an association between Beh&ccedil;et syndrome and elevated homocysteine levels; hyperhomocysteinemia may be an acquired and potentially reversible risk factor for Beh&ccedil;et syndrome, may be a clinical marker of disease activity, and may be associated with thrombosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,147,182-184\" class=\"abstract_t\">14,147,182-184</a>].</p><p>Vascular endothelial growth factor levels are higher in patients with Beh&ccedil;et syndrome and have been associated with increased disease activity and NO concentrations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/60,185-187\" class=\"abstract_t\">60,185-187</a>]. Cerebrospinal fluid VEGF levels were higher in a group of Beh&ccedil;et syndrome patients with neurologic involvement compared with patients with noninflammatory neurologic diseases [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/188\" class=\"abstract_t\">188</a>]. Polymorphisms of the VGEF gene are associated with Beh&ccedil;et syndrome, but not in all populations [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/42,45,46,189\" class=\"abstract_t\">42,45,46,189</a>].</p><p>IgM-antiendothelial antibodies were found to be reactive with alpha enolase in some Korean Beh&ccedil;et syndrome patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/190\" class=\"abstract_t\">190</a>]. A follow-up study demonstrated IgM-antiendothelial antibodies in patients with Beh&ccedil;et syndrome (56 percent), systemic sclerosis (71.4 percent), rheumatoid arthritis (65 percent), Takayasu (50 percent), dermatomyositis (52.9 percent), and mixed connective tissue disease (45.5 percent); these antibodies were associated with the presence of vascular lesions in patients with Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/191\" class=\"abstract_t\">191</a>]. Leptin is expressed by endothelial cells, and increased levels in Beh&ccedil;et syndrome may correlate with disease activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/192\" class=\"abstract_t\">192</a>]. Endothelial cell activation and a generalized hypercoagulable state were observed in 24 patients with ocular Beh&ccedil;et syndrome characterized by increased mean levels of factor VIII, factor XI, von Willebrand factor antigen and ristocetin, antithrombin III, and fibrinogen [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/193\" class=\"abstract_t\">193</a>].</p><p>A generalized hypercoagulable state appears to exist in many Beh&ccedil;et syndrome patients. Thrombin formation is increased, and fibrinolysis is decreased [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,194,195\" class=\"abstract_t\">14,194,195</a>]. Lower activated protein C (APC) and soluble thrombomodulin concentrations in the plasma of patients with Beh&ccedil;et syndrome have been observed. Thrombomodulin, present on the endothelial cell surface, binds thrombin, and the substrate specificity of thrombin thus bound is changed so that it preferentially activates protein C rather than cleaving fibrinogen. The APC generated at the endothelial surface is an important inhibitor of coagulation. (See <a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">&quot;Overview of hemostasis&quot;</a>.)</p><p>The findings of significantly decreased mean concentrations of plasma APC among 39 Spanish patients with Beh&ccedil;et syndrome versus healthy controls, and of lower levels of APC among patients with Beh&ccedil;et syndrome who had a prior thromboembolic episode versus those who had not, suggest that an acquired deficiency of APC in Beh&ccedil;et syndrome may contribute to the risk of thrombosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/196\" class=\"abstract_t\">196</a>]. Platelet activity is increased in Beh&ccedil;et syndrome patients [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/197\" class=\"abstract_t\">197</a>]. Studies have shown decreased erythrocyte deformability in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/198,199\" class=\"abstract_t\">198,199</a>]. Tissue-type plasminogen activator levels are lower in patients with deep venous thrombosis who have Beh&ccedil;et syndrome than in those who do not have Beh&ccedil;et syndrome; this suggests a defect in fibrinolysis in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/200\" class=\"abstract_t\">200</a>].</p><p>A study of 98 Beh&ccedil;et syndrome patients and 70 controls demonstrated in the Beh&ccedil;et syndrome patients impaired thrombin-catalyzed fibrin formation and fibrin susceptibility to plasmin-induced lysis, associated with increased plasma oxidative stress markers, and increased neutrophil NADPH oxidase activity and reactive oxygen species production, which supports the role of neutrophil activation in thrombus formation in Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/201\" class=\"abstract_t\">201</a>].</p><p>Thrombophilic factors such as factor V Leiden and prothrombin G20210A gene have not been linked to Beh&ccedil;et syndrome, although Beh&ccedil;et syndrome patients with coexisting thrombophilic factors may be at higher risk for thrombosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/202,203\" class=\"abstract_t\">202,203</a>]. Levels of the fibrinolytic inhibitors thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) were higher in Beh&ccedil;et syndrome patients than in controls, particularly in those patients with thrombosis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/204\" class=\"abstract_t\">204</a>].</p><p>However, the majority of available evidence suggests that the pathogenesis of thrombosis in Beh&ccedil;et syndrome is probably not due to a hypercoagulable state but rather to vascular damage induced by inflammation or intrinsic endothelial dysfunction that, by itself, may serve as a source of thrombogenic stimuli [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/205-207\" class=\"abstract_t\">205-207</a>].</p><p>Patients with Beh&ccedil;et syndrome have increased intima-media thickness and decreased arterial distensibility compared with controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/208\" class=\"abstract_t\">208</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Neutrophil activation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polymorphonuclear leukocytes (PMNs) are activated in Beh&ccedil;et syndrome.</p><p>In Beh&ccedil;et syndrome, PMN motility is increased. Increased circulating levels of cytokines such as IL-8 and TNF-alpha lead to activation of PMNs and the endothelial surface [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/209,210\" class=\"abstract_t\">209,210</a>]. Cell surface markers indicative of activation, such as CD64, are increased in patients with active disease to levels similar to those of patients with sepsis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/211\" class=\"abstract_t\">211</a>]. PMNs exhibit increased motility and enhanced adhesion to endothelial cells in vitro, a property due, in part, to increased expression of cell surface receptors including CD11a, CD18, and ICAM-1 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/212\" class=\"abstract_t\">212</a>]. Neutrophil binding to the endothelium is also facilitated by upregulated surface expression of adhesion molecules such as E-selectin. Increased E-selectin on the luminal surface favors neutrophil adhesion and facilitates neutrophil migration into the wall of the affected vessel and beyond [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/171\" class=\"abstract_t\">171</a>].</p><p>Measurements of serum-soluble levels of this activity have been observed. Serum-soluble ICAM-1 is increased in patients with Beh&ccedil;et syndrome, and the concentration may correlate with disease activity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/96,213\" class=\"abstract_t\">96,213</a>]. The serum of patients with active Beh&ccedil;et syndrome may promote increased E-selectin presentation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/99\" class=\"abstract_t\">99</a>]. Some of this may be due to anti-endothelial antibodies [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/171\" class=\"abstract_t\">171</a>]. Serum-soluble levels of selectin have been shown to be elevated in patients with active untreated disease but not if it is treated or inactive [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/214,215\" class=\"abstract_t\">214,215</a>]. A study of patients with Beh&ccedil;et retinal vasculitis showed elevated levels of soluble E-selectin, s-ICAM-1, and Interferon-beta. In vitro studies showed that these were produced by activated retinal vascular endothelial cells and that this could be inhibited by pretreatment with anti-Toll-like receptor 3 [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/216\" class=\"abstract_t\">216</a>].</p><p>The protein actin is required for PMN mobility. The presence of high levels of a truncated actin with an N-terminus of Met-44 has been observed in neutrophils from Beh&ccedil;et syndrome patients; PMN-elastase responsible for this cleavage has been isolated. Resulting altered PMN activity has been described [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/217,218\" class=\"abstract_t\">217,218</a>].</p><p>Increased amount of reactive oxygen species suggest neutrophil mediated immunity [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,219,220\" class=\"abstract_t\">14,219,220</a>]. Endogenous free radical scavenging enzymes appear to be reduced in Beh&ccedil;et syndrome, creating an imbalance in the oxidant antioxidant equilibrium [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,95\" class=\"abstract_t\">14,95</a>].</p><p>Serum granulocyte colony-stimulating factor (G-CSF) levels and neutrophil apoptosis are increased in active Beh&ccedil;et syndrome patients compared with controls [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/221\" class=\"abstract_t\">221</a>].</p><p>Markers of neutrophil activity have been proposed as possible indicators of disease activity and severity. These include polymorphonuclear elastase, plasma myeloperoxidase, and advanced oxidation protein products [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/96,222,223\" class=\"abstract_t\">96,222,223</a>].</p><p>Matrix metalloproteinases play a role in leucocyte invasion of the central nervous system. Elevated levels of matrix metalloprotein-9 have been described in Beh&ccedil;et syndrome patients compared with controls, and levels correlated with CSF neutrophil and mononuclear cells in a study of Beh&ccedil;et syndrome patients with neurologic disease [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/224\" class=\"abstract_t\">224</a>].</p><p>Beh&ccedil;et arthritis is characterized by synovial inflammation with significant neutrophilic greater than lymphocytic inflammation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/225\" class=\"abstract_t\">225</a>].</p><p>Monocytes from patients with Beh&ccedil;et syndrome have enhanced activity, with increased differentiation and expression of adhesion molecules and cytokines, which, in turn, leads to neutrophil activation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14,226,227\" class=\"abstract_t\">14,226,227</a>].</p><p class=\"headingAnchor\" id=\"H2522010038\"><span class=\"h2\">Epigenetic alterations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Epigenetic changes may contribute to the pathophysiology of Beh&ccedil;et syndrome [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/228\" class=\"abstract_t\">228</a>]. Epigenetics is the study of phenotypic cellular changes that occur due to changes in how genes are read or utilized by the cell and not due to changes in the gene sequences themselves.</p><p>Alterations of DNA methylation of immune cells in Beh&ccedil;et syndrome has been described. DNA methylation, addition of a methyl group to a carbon in cytosine rings within CpG dinucleotides, results in gene transcription repression. Hypomethylation allows ongoing transcription activity, and alterations in DNA methylation have been described in a number of immune diseases. A study of DNA methylation of monocytes and CD4+ T cells from 16 Beh&ccedil;et syndrome patients compared with 12 healthy controls showed altered methylation patterns in genes involved in cytoskeletal dynamics, and these alterations were changed by disease treatment [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/229\" class=\"abstract_t\">229</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologic examination of involved tissue in patients with Beh&ccedil;et syndrome frequently reveals a vasculitis, although this finding may not be demonstrated in all lesions [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/6,230\" class=\"abstract_t\">6,230</a>]. The classic Beh&ccedil;et lesion is necrotizing leukocytoclastic obliterative perivasculitis and venous thrombosis with lymphocytic infiltration of capillaries, veins, and arteries of all sizes. Cellular infiltration is often in a perivascular distribution; neutrophils and CD4+ T lymphocytes are present around the vasa vasorum and perivascular area. When a frank leukocytoclastic vasculitis is present, there may be endothelial swelling, extravasation of erythrocytes, and fibrinoid necrosis of blood vessel walls. Thrombosis is often present [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Mucocutaneous lesions demonstrate lymphocytic infiltration, immunoglobulin and complement deposition, and liquefaction-degeneration at the dermal-epidermal junction in association with necrosis and ulcer formation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/231,232\" class=\"abstract_t\">231,232</a>].</p><p>Neutrophilic and mononuclear infiltrates are frequently observed in spontaneous acute lesions and following testing for pathergy [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/6,233\" class=\"abstract_t\">6,233</a>]. Histopathologic evaluation of 23 positive pathergy responses revealed mixed type inflammatory cell infiltrate in 39.1 percent, lobular panniculitis without vasculitis in 8.7 percent, neutrophilic infiltrate in 8.7 percent, and lymphocytic infiltration in 21.7 percent, with endothelial swelling and thickening in 17.3 percent, erythrocyte extravasation in 26 percent, perivascular cell infiltrate in 13 percent, lymphocytic vascular reaction in 8.6 percent, lymphocytic vasculitis in 13 percent, and leukocytoclastic vasculitis in 21.7 percent [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/234\" class=\"abstract_t\">234</a>].</p><p>Papulopustular lesions may show leukocytoclastic vasculitis with IgM, IgG, C3, and fibrin deposits, consistent with an immune complex vasculitis [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/235,236\" class=\"abstract_t\">235,236</a>]. Pustular skin lesions are often not sterile and may contain <em>Staphylococcus aureus</em> and Prevotella species [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/237\" class=\"abstract_t\">237</a>].</p><p>Erythema nodosum type lesions in Beh&ccedil;et syndrome demonstrate lobular or mixed lobular and septal panniculitis; demonstrate variable numbers of neutrophils, lymphocytes, and histiocytes; and often show leukocytoclastic vasculitis.</p><p>Ocular Beh&ccedil;et lesions may show leukocyte infiltration around blood vessels, occlusive retinal perivasculitis, and thrombosis. Nongranulomatous panuveitis is characteristic. During active disease, neutrophils may be present in the anterior chamber of the eye, as well as the corneal epithelium, iris, ciliary body, and choroids [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14\" class=\"abstract_t\">14</a>].</p><p>Central nervous system lesions in Beh&ccedil;et syndrome demonstrate perivascular cuffing of T lymphocytes and monocytes, as well as apoptosis of affected neurons [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/238\" class=\"abstract_t\">238</a>]. Involved areas include the spinal cord, brainstem (including the pons, medulla oblongata, and midbrain), cerebellum, basal ganglia, thalamus, internal capsule, and periventricular white matter.</p><p>Although renal involvement is infrequent and usually mild, when present, renal histology may show mesangial proliferation, proliferative glomerulonephritis, crescent formation, and deposits of immunoglobulin, complement, and immune complex in the glomeruli [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/239\" class=\"abstract_t\">239</a>].</p><p>Beh&ccedil;et arthritis is characterized by synovial inflammation with significant neutrophilic greater than lymphocytic inflammation [<a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/225\" class=\"abstract_t\">225</a>].</p><p class=\"headingAnchor\" id=\"H4084931802\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-vasculitis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Vasculitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17358645\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Many, but not all, clinical manifestations of Beh&ccedil;et syndrome are believed to be due to vasculitis. Among the systemic vasculitides, Beh&ccedil;et syndrome is remarkable for its ability to involve blood vessels of all sizes (small, medium, and large) on both the arterial and venous sides of the circulation. Beh&ccedil;et syndrome is more common (and often more severe) along the ancient silk road, which extends from eastern Asia to the Mediterranean. It is most common in Turkey (80 to 370 cases per 100,000). The prevalence is from 1 per 15,000 to 1 per 500,000 in Northern American and Northern European countries. It typically affects young adults 20 to 40 years of age. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The underlying cause of Beh&ccedil;et syndrome is unknown. As with autoimmune diseases, the disorder may represent aberrant immune activity triggered by exposure to an agent, perhaps infectious, in patients with a genetic predisposition to develop the disease. Proposed triggering agents include viral and bacterial antigens or other environmental sources, such as chemicals or heavy metals. Although still a possible contributor, direct infection of affected tissues has not been observed. (See <a href=\"#H3\" class=\"local\">'Etiology and pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Genetic predisposition to the disease is likely polygenic. Genetic influences include association with certain human leukocyte antigens (HLA), including HLA-B51, but both HLA and non-HLA genes may play a role. (See <a href=\"#H4\" class=\"local\">'Genetic'</a> above and <a href=\"#H5\" class=\"local\">'HLA genes'</a> above and <a href=\"#H6\" class=\"local\">'Non-HLA genes'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Studies suggest a possible pathogenic role of certain bacterial antigens that have cross-reactivity with human peptides. Different studies have implicated various antigens and organisms, including heat shock proteins, streptococcal antigens, <em>Helicobacter pylori</em>, Herpes simplex virus, and parvovirus B19.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered innate immune function has been suggested by some studies. These include investigations suggesting deficiencies in mannose-binding lectin and alterations in the expression of toll-like receptors. (See <a href=\"#H7\" class=\"local\">'Altered bacteria and bacteria response'</a> above and <a href=\"#H8\" class=\"local\">'Altered innate immune function'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are alterations in the numbers of T cell subpopulations and evidence of cellular activation. Autoreactive T cells appear to play a critical role in the pathogenesis of Beh&ccedil;et syndrome. A T helper (Th) 1 predominant response has been observed in many studies of Beh&ccedil;et syndrome, but some studies have shown evidence for a Th2 response. There may be a mix of Th1 and Th2 activity in Beh&ccedil;et syndrome and increased activity of Th17 cells. (See <a href=\"#H9\" class=\"local\">'Cellular immunity and cytokines'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to cellular immune activation, there is also evidence of humoral immune activation in Beh&ccedil;et syndrome, and autoantibodies have been described against a number of targets. Immune complexes may also play a role. (See <a href=\"#H10\" class=\"local\">'Autoantibody and immune complex formation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Endothelial dysfunction is a characteristic finding in Beh&ccedil;et syndrome. Endothelium-dependent flow-mediated dilation is reduced, and endothelial activation in affected blood vessels is a mediator of vascular inflammation as well as thrombosis in Beh&ccedil;et syndrome.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polymorphonuclear leukocytes (PMNs) are activated in Beh&ccedil;et syndrome; PMNs exhibit increased motility and enhanced adhesion to endothelial cells in vitro. (See <a href=\"#H11\" class=\"local\">'Endothelial activation and altered coagulation'</a> above and <a href=\"#H12\" class=\"local\">'Neutrophil activation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epigenetic changes may contribute to the pathophysiology of Beh&ccedil;et syndrome. Alterations of DNA methylation of immune cells in Beh&ccedil;et syndrome has been described. (See <a href=\"#H2522010038\" class=\"local\">'Epigenetic alterations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Histologic examination of involved tissue in patients with Beh&ccedil;et syndrome frequently reveals a vasculitis, although this finding may not be demonstrated in all lesions. The classic Beh&ccedil;et lesion is necrotizing leukocytoclastic obliterative perivasculitis and venous thrombosis with lymphocytic infiltration of capillaries, veins, and arteries of all sizes. Cellular infiltration is often in a perivascular distribution; neutrophils and CD4+ T lymphocytes are present around the vasa vasorum and perivascular area. Other histologic findings may include panniculitis in erythema nodosum-like lesions and neutrophilic and mononuclear infiltrates in spontaneous acute lesions and following testing for pathergy. (See <a href=\"#H13\" class=\"local\">'Pathology'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/1\" class=\"nounderline abstract_t\">Sakane T, Takeno M, Suzuki N, Inaba G. Beh&ccedil;et's disease. N Engl J Med 1999; 341:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/2\" class=\"nounderline abstract_t\">Mahr A, Belarbi L, Wechsler B, et al. Population-based prevalence study of Beh&ccedil;et's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58:3951.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/3\" class=\"nounderline abstract_t\">Yazici H, Seyahi E, Yurdakul S. Beh&ccedil;et's syndrome is not so rare: why do we need to know? Arthritis Rheum 2008; 58:3640.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/4\" class=\"nounderline abstract_t\">Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Beh&ccedil;et's disease in the US: a population-based study. Arthritis Rheum 2009; 61:600.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/5\" class=\"nounderline abstract_t\">Mahr A, Maldini C. [Epidemiology of Beh&ccedil;et's disease]. Rev Med Interne 2014; 35:81.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/6\" class=\"nounderline abstract_t\">Direskeneli H. Beh&ccedil;et's disease: infectious aetiology, new autoantigens, and HLA-B51. Ann Rheum Dis 2001; 60:996.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/7\" class=\"nounderline abstract_t\">de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Beh&ccedil;et's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 2009; 61:1287.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/8\" class=\"nounderline abstract_t\">Arber N, Klein T, Meiner Z, et al. Close association of HLA-B51 and B52 in Israeli patients with Beh&ccedil;et's syndrome. Ann Rheum Dis 1991; 50:351.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/9\" class=\"nounderline abstract_t\">Salvarani C, Boiardi L, Mantovani V, et al. Association of MICA alleles and HLA-B51 in Italian patients with Beh&ccedil;et's disease. J Rheumatol 2001; 28:1867.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/10\" class=\"nounderline abstract_t\">K&ouml;tter I, G&uuml;naydin I, St&uuml;biger N, et al. Comparative analysis of the association of HLA-B*51 suballeles with Beh&ccedil;et's disease in patients of German and Turkish origin. Tissue Antigens 2001; 58:166.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/11\" class=\"nounderline abstract_t\">Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Beh&ccedil;et's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 2003; 48:807.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/12\" class=\"nounderline abstract_t\">Baskan EB, Yilmaz E, Saricaoglu H, et al. Detection of parvovirus B19 DNA in the lesional skin of patients with Beh&ccedil;et's disease. Clin Exp Dermatol 2007; 32:186.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/13\" class=\"nounderline abstract_t\">Mizuki N, Meguro A, Tohnai I, et al. Association of Major Histocompatibility Complex Class I Chain-Related Gene A and HLA-B Alleles with Beh&ccedil;et's Disease in Turkey. Jpn J Ophthalmol 2007; 51:431.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/14\" class=\"nounderline abstract_t\">Evereklioglu C. Current concepts in the etiology and treatment of Beh&ccedil;et disease. Surv Ophthalmol 2005; 50:297.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/15\" class=\"nounderline abstract_t\">Bennani N, Atouf O, Benseffaj N, et al. [HLA polymorphism and Beh&ccedil;et's disease in Moroccan population]. Pathol Biol (Paris) 2009; 57:403.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/16\" class=\"nounderline abstract_t\">Kamiishi T, Itoh Y, Meguro A, et al. [Four-digit allele genotyping of HLA-A and HLA-B genes in Japanese patients with Beh&ccedil;et's disease (BD) by a PCR-SSOP-luminex method and stratification analysis according to each major symptom of BD]. Nippon Ganka Gakkai Zasshi 2008; 112:451.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/17\" class=\"nounderline abstract_t\">Meguro A, Inoko H, Ota M, et al. Genetics of Beh&ccedil;et disease inside and outside the MHC. Ann Rheum Dis 2010; 69:747.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/18\" class=\"nounderline abstract_t\">Takeuchi M, Kastner DL, Remmers EF. The immunogenetics of Beh&ccedil;et's disease: A comprehensive review. J Autoimmun 2015; 64:137.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/19\" class=\"nounderline abstract_t\">G&uuml;l A, Hajeer AH, Worthington J, et al. Evidence for linkage of the HLA-B locus in Beh&ccedil;et's disease, obtained using the transmission disequilibrium test. Arthritis Rheum 2001; 44:239.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/20\" class=\"nounderline abstract_t\">Sakane T, Takeno M. Novel approaches to Beh&ccedil;et's disease. Expert Opin Investig Drugs 2000; 9:1993.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/21\" class=\"nounderline abstract_t\">Ermakova NA, Alekberova ZS, Prokaeva TB, Poljanskaja IB. Frequency of HLA in patients with Beh&ccedil;et's disease and association with occlusive retinal vasculitis. Adv Exp Med Biol 2003; 528:231.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/22\" class=\"nounderline abstract_t\">Choukri F, Chakib A, Himmich H, et al. HLA-B phenotype modifies the course of Beh&ccedil;et's disease in Moroccan patients. Tissue Antigens 2003; 61:92.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/23\" class=\"nounderline abstract_t\">G&uuml;l A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Beh&ccedil;et's disease. Rheumatology (Oxford) 2001; 40:668.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/24\" class=\"nounderline abstract_t\">Mizuki N, Inoko H, Ohno S. Pathogenic gene responsible for the predisposition of Beh&ccedil;et's disease. Int Rev Immunol 1997; 14:33.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/25\" class=\"nounderline abstract_t\">Gebreselassie D, Spiegel H, Vukmanovic S. Sampling of major histocompatibility complex class I-associated peptidome suggests relatively looser global association of HLA-B*5101 with peptides. Hum Immunol 2006; 67:894.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/26\" class=\"nounderline abstract_t\">Wildner G, Thurau SR. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 1994; 24:2579.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/27\" class=\"nounderline abstract_t\">Ota M, Mizuki N, Katsuyama Y, et al. The critical region for Beh&ccedil;et disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet 1999; 64:1406.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/28\" class=\"nounderline abstract_t\">Mu&ntilde;oz-Sa&aacute; I, Cambra A, Pallar&eacute;s L, et al. Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Beh&ccedil;et's disease. Scand J Immunol 2006; 64:77.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/29\" class=\"nounderline abstract_t\">Hughes EH, Collins RW, Kondeatis E, et al. Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behcet's disease in Caucasian patients. Tissue Antigens 2005; 66:195.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/30\" class=\"nounderline abstract_t\">G&uuml;l A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Beh&ccedil;et's disease to chromosome 6p22-23. Arthritis Rheum 2001; 44:2693.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/31\" class=\"nounderline abstract_t\">Hughes T, Coit P, Adler A, et al. Identification of multiple independent susceptibility loci in the HLA region in Beh&ccedil;et's disease. Nat Genet 2013; 45:319.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/32\" class=\"nounderline abstract_t\">Kirino Y, Bertsias G, Ishigatsubo Y, et al. Genome-wide association analysis identifies new susceptibility loci for Beh&ccedil;et's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet 2013; 45:202.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/33\" class=\"nounderline abstract_t\">Akpolat T, Ko&ccedil; Y, Yeniay I, et al. Familial Beh&ccedil;et's disease. Eur J Med 1992; 1:391.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/34\" class=\"nounderline abstract_t\">Kon&eacute;-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Beh&ccedil;et's disease: high frequency in siblings and parents of pediatric probands. J Pediatr 1999; 135:89.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/35\" class=\"nounderline abstract_t\">Fresko I, Soy M, Hamuryudan V, et al. Genetic anticipation in Beh&ccedil;et's syndrome. Ann Rheum Dis 1998; 57:45.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/36\" class=\"nounderline abstract_t\">Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Beh&ccedil;et disease. Proc Natl Acad Sci U S A 1997; 94:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/37\" class=\"nounderline abstract_t\">Wei F, Zhang YU, Li W. A meta-analysis of the association between Beh&ccedil;et's disease and MICA-A6. Biomed Rep 2016; 4:741.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/38\" class=\"nounderline abstract_t\">Zhang J, Liao D, Yang L, Hou S. Association between Functional MICA-TM and Behcet's Disease: A Systematic Review and Meta-analysis. Sci Rep 2016; 6:21033.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/39\" class=\"nounderline abstract_t\">Lee YH, Song GG. Associations between major histocompatibility complex class I chain-related gene A polymorphisms and susceptibility to Behcet's disease. A meta-analysis. Z Rheumatol 2015; 74:714.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/40\" class=\"nounderline abstract_t\">Guasp P, Barnea E, Gonz&aacute;lez-Escribano MF, et al. The Beh&ccedil;et's disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing. J Biol Chem 2017; 292:9680.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/41\" class=\"nounderline abstract_t\">Guasp P, Alvarez-Navarro C, Gomez-Molina P, et al. The Peptidome of Beh&ccedil;et's Disease-Associated HLA-B*51:01 Includes Two Subpeptidomes Differentially Shaped by Endoplasmic Reticulum Aminopeptidase 1. Arthritis Rheumatol 2016; 68:505.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/42\" class=\"nounderline abstract_t\">Salvarani C, Boiardi L, Casali B, et al. Endothelial nitric oxide synthase gene polymorphisms in Beh&ccedil;et's disease. J Rheumatol 2002; 29:535.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/43\" class=\"nounderline abstract_t\">Gunesacar R, Erken E, Bozkurt B, et al. Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease. Int J Immunogenet 2007; 34:45.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/44\" class=\"nounderline abstract_t\">Karasneh J, G&uuml;l A, Ollier WE, et al. Whole-genome screening for susceptibility genes in multicase families with Beh&ccedil;et's disease. Arthritis Rheum 2005; 52:1836.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/45\" class=\"nounderline abstract_t\">Karasneh JA, Hajeer AH, Silman A, et al. Polymorphisms in the endothelial nitric oxide synthase gene are associated with Beh&ccedil;et's disease. Rheumatology (Oxford) 2005; 44:614.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/46\" class=\"nounderline abstract_t\">Salvarani C, Boiardi L, Casali B, et al. Vascular endothelial growth factor gene polymorphisms in Beh&ccedil;et's disease. J Rheumatol 2004; 31:1785.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/47\" class=\"nounderline abstract_t\">Kim JU, Chang HK, Lee SS, et al. Endothelial nitric oxide synthase gene polymorphisms in Beh&ccedil;et's disease and rheumatic diseases with vasculitis. Ann Rheum Dis 2003; 62:1083.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/48\" class=\"nounderline abstract_t\">Verity DH, Wallace GR, Vaughan RW, et al. HLA and tumour necrosis factor (TNF) polymorphisms in ocular Beh&ccedil;et's disease. Tissue Antigens 1999; 54:264.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/49\" class=\"nounderline abstract_t\">Lee EB, Kim JY, Lee YJ, et al. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol 2003; 64:614.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/50\" class=\"nounderline abstract_t\">Kamoun M, Chelbi H, Houman MH, et al. Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease. Hum Immunol 2007; 68:201.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/51\" class=\"nounderline abstract_t\">Nakao K, Isashiki Y, Sonoda S, et al. Nitric oxide synthase and superoxide dismutase gene polymorphisms in Beh&ccedil;et disease. Arch Ophthalmol 2007; 125:246.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/52\" class=\"nounderline abstract_t\">Tursen U, Tamer L, Api H, et al. Cytochrome P450 polymorphisms in patients with Behcet's disease. Int J Dermatol 2007; 46:153.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/53\" class=\"nounderline abstract_t\">Alayli G, Aydin F, Coban AY, et al. T helper 1 type cytokines polymorphisms: association with susceptibility to Beh&ccedil;et's disease. Clin Rheumatol 2007; 26:1299.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/54\" class=\"nounderline abstract_t\">Lee YJ, Kang SW, Park JJ, et al. Interleukin-18 promoter polymorphisms in patients with Beh&ccedil;et's disease. Hum Immunol 2006; 67:812.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/55\" class=\"nounderline abstract_t\">Akman A, Sallakci N, Coskun M, et al. TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Beh&ccedil;et's disease. Br J Dermatol 2006; 155:350.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/56\" class=\"nounderline abstract_t\">Chmaisse HN, Fakhoury HA, Salti NN, Makki RF. The ICAM-1 469 T/C gene polymorphism but not 241 G/A is associated with Beh&ccedil;ets disease in the Lebanese population. Saudi Med J 2006; 27:604.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/57\" class=\"nounderline abstract_t\">Fei Y, Webb R, Cobb BL, et al. Identification of novel genetic susceptibility loci for Beh&ccedil;et's disease using a genome-wide association study. Arthritis Res Ther 2009; 11:R66.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/58\" class=\"nounderline abstract_t\">Touma Z, Farra C, Hamdan A, et al. TNF polymorphisms in patients with Beh&ccedil;et disease: a meta-analysis. Arch Med Res 2010; 41:142.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/59\" class=\"nounderline abstract_t\">Dilek K, Oz&ccedil;imen AA, Saricao&#287;lu H, et al. Cytokine gene polymorphisms in Beh&ccedil;et's disease and their association with clinical and laboratory findings. Clin Exp Rheumatol 2009; 27:S73.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/60\" class=\"nounderline abstract_t\">Kamoun M, Houman MH, Hamzaoui A, Hamzaoui K. Vascular endothelial growth factor gene polymorphisms and serum levels in Beh&ccedil;et's disease. Tissue Antigens 2008; 72:581.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/61\" class=\"nounderline abstract_t\">Park KS, Baek JA, Do JE, et al. CTLA4 gene polymorphisms and soluble CTLA4 protein in Behcet's disease. Tissue Antigens 2009; 74:222.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/62\" class=\"nounderline abstract_t\">Horie Y, Meguro A, Ota M, et al. Association of TLR4 polymorphisms with Behcet's disease in a Korean population. Rheumatology (Oxford) 2009; 48:638.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/63\" class=\"nounderline abstract_t\">Sousa I, Shahram F, Francisco D, et al. Brief report: association of CCR1, KLRC4, IL12A-AS1, STAT4, and ERAP1 With Beh&ccedil;et's disease in Iranians. Arthritis Rheumatol 2015; 67:2742.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/64\" class=\"nounderline abstract_t\">G&uuml;l A. Pathogenesis of Beh&ccedil;et's disease: autoinflammatory features and beyond. Semin Immunopathol 2015; 37:413.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/65\" class=\"nounderline abstract_t\">Hu J, Hou S, Zhu X, et al. Interleukin-10 gene polymorphisms are associated with Behcet's disease but not with Vogt-Koyanagi-Harada syndrome in the Chinese Han population. Mol Vis 2015; 21:589.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/66\" class=\"nounderline abstract_t\">Ombrello MJ, Kastner DL, Remmers EF. Endoplasmic reticulum-associated amino-peptidase 1 and rheumatic disease: genetics. Curr Opin Rheumatol 2015; 27:349.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/67\" class=\"nounderline abstract_t\">Yal&ccedil;in B, Atakan N, Dogan S. Association of interleukin-23 receptor gene polymorphism with Beh&ccedil;et disease. Clin Exp Dermatol 2014; 39:881.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/68\" class=\"nounderline abstract_t\">Livneh A, Aksentijevich I, Langevitz P, et al. A single mutated MEFV allele in Israeli patients suffering from familial Mediterranean fever and Beh&ccedil;et's disease (FMF-BD). Eur J Hum Genet 2001; 9:191.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/69\" class=\"nounderline abstract_t\">Kogan A, Shinar Y, Lidar M, et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001; 102:272.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/70\" class=\"nounderline abstract_t\">Rabinovich E, Shinar Y, Leiba M, et al. Common FMF alleles may predispose to development of Behcet's disease with increased risk for venous thrombosis. Scand J Rheumatol 2007; 36:48.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/71\" class=\"nounderline abstract_t\">Dursun A, Durakbasi-Dursun HG, Zamani AG, et al. Genetic analysis of MEFV gene pyrin domain in patients with Beh&ccedil;et's disease. Mediators Inflamm 2006; 2006:41783.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/72\" class=\"nounderline abstract_t\">Direskeneli H, Hasan A, Shinnick T, et al. Recognition of B-cell epitopes of the 65 kDa HSP in Beh&ccedil;et's disease. Scand J Immunol 1996; 43:464.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/73\" class=\"nounderline abstract_t\">de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm 2001; 9:85.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/74\" class=\"nounderline abstract_t\">Suzuki Y, Hoshi K, Matsuda T, Mizushima Y. Increased peripheral blood gamma delta+ T cells and natural killer cells in Beh&ccedil;et's disease. J Rheumatol 1992; 19:588.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/75\" class=\"nounderline abstract_t\">Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Beh&ccedil;et's disease--a multicenter study. The Behcet's Disease Research Committee of Japan. J Rheumatol 1989; 16:506.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/76\" class=\"nounderline abstract_t\">Mumcu G, Inanc N, Aydin SZ, et al. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Beh&ccedil;et's disease. Clin Exp Rheumatol 2009; 27:S32.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/77\" class=\"nounderline abstract_t\">Seoudi N, Bergmeier LA, Drobniewski F, et al. The oral mucosal and salivary microbial community of Beh&ccedil;et's syndrome and recurrent aphthous stomatitis. J Oral Microbiol 2015; 7:27150.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/78\" class=\"nounderline abstract_t\">Consolandi C, Turroni S, Emmi G, et al. Beh&ccedil;et's syndrome patients exhibit specific microbiome signature. Autoimmun Rev 2015; 14:269.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/79\" class=\"nounderline abstract_t\">Yokota K, Hayashi S, Fujii N, et al. Antibody response to oral streptococci in Beh&ccedil;et's disease. Microbiol Immunol 1992; 36:815.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/80\" class=\"nounderline abstract_t\">Isogai E, Ohno S, Kotake S, et al. Chemiluminescence of neutrophils from patients with Beh&ccedil;et's disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 1990; 35:43.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/81\" class=\"nounderline abstract_t\">Calg&uuml;neri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Beh&ccedil;et's disease. Dermatology 1996; 192:125.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/82\" class=\"nounderline abstract_t\">Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet's disease. Cell Immunol 1992; 140:410.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/83\" class=\"nounderline abstract_t\">Mochizuki M, Suzuki N, Takeno M, et al. Fine antigen specificity of human gamma delta T cell lines (V gamma 9+) established by repetitive stimulation with a serotype (KTH-1) of a gram-positive bacterium, Streptococcus sanguis. Eur J Immunol 1994; 24:1536.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/84\" class=\"nounderline abstract_t\">Evereklioglu C, Er H, T&uuml;rk&ouml;z Y, Cekmen M. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Beh&ccedil;et's disease. Mediators Inflamm 2002; 11:87.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/85\" class=\"nounderline abstract_t\">Calg&uuml;neri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Beh&ccedil;et's disease. A randomized clinical trial. Arthritis Rheum 1996; 39:2062.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/86\" class=\"nounderline abstract_t\">Apan TZ, G&uuml;rsel R, Dolgun A. Increased seropositivity of Helicobacter pylori cytotoxin-associated gene-A in Beh&ccedil;et's disease. Clin Rheumatol 2007; 26:885.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/87\" class=\"nounderline abstract_t\">Inanc N, Mumcu G, Birtas E, et al. Serum mannose-binding lectin levels are decreased in behcet's disease and associated with disease severity. J Rheumatol 2005; 32:287.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/88\" class=\"nounderline abstract_t\">Yavuz S, Elbir Y, Tulunay A, et al. Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcet's disease etiopathogenesis. Rheumatol Int 2008; 28:401.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/89\" class=\"nounderline abstract_t\">Seoudi N, Bergmeier LA, Hagi-Pavli E, et al. The role of TLR2 and 4 in Beh&ccedil;et's disease pathogenesis. Innate Immun 2014; 20:412.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/90\" class=\"nounderline abstract_t\">Liu X, Wang C, Ye Z, et al. Higher expression of Toll-like receptors 2, 3, 4, and 8 in ocular Behcet's disease. Invest Ophthalmol Vis Sci 2013; 54:6012.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/91\" class=\"nounderline abstract_t\">Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of Toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford) 2008; 47:840.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/92\" class=\"nounderline abstract_t\">Liang L, Tan X, Zhou Q, et al. IL-1&beta; triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Beh&ccedil;et's disease. Invest Ophthalmol Vis Sci 2013; 54:402.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/93\" class=\"nounderline abstract_t\">Nara K, Kurokawa MS, Chiba S, et al. Involvement of innate immunity in the pathogenesis of intestinal Beh&ccedil;et's disease. Clin Exp Immunol 2008; 152:245.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/94\" class=\"nounderline abstract_t\">Lockwood CM, Hale G, Waldman H, Jayne DR. Remission induction in Beh&ccedil;et's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford) 2003; 42:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/95\" class=\"nounderline abstract_t\">Erkili&ccedil; K, Evereklioglu C, Cekmen M, et al. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Beh&ccedil;et's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003; 12:107.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/96\" class=\"nounderline abstract_t\">Calis M, Ates F, Yazici C, et al. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Beh&ccedil;et's disease. Rheumatol Int 2005; 25:452.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/97\" class=\"nounderline abstract_t\">Canpolat F, Unver M, Eskio&#287;lu F, et al. Serum and erythrocyte adenosine deaminase activities in patients with Beh&ccedil;et's disease. Int J Dermatol 2006; 45:1053.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/98\" class=\"nounderline abstract_t\">Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Beh&ccedil;et's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31:205.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/99\" class=\"nounderline abstract_t\">Raziuddin S, al-Dalaan A, Bahabri S, et al. Divergent cytokine production profile in Beh&ccedil;et's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 1998; 25:329.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/100\" class=\"nounderline abstract_t\">Dalghous AM, Freysdottir J, Fortune F. Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behcet's disease (BD) and recurrent aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006; 35:472.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/101\" class=\"nounderline abstract_t\">Sugi-Ikai N, Nakazawa M, Nakamura S, et al. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Beh&ccedil;et's disease. Invest Ophthalmol Vis Sci 1998; 39:996.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/102\" class=\"nounderline abstract_t\">Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Beh&ccedil;et's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42:1967.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/103\" class=\"nounderline abstract_t\">Boiardi L, Salvarani C, Casali B, et al. Intercellular adhesion molecule-1 gene polymorphisms in Beh&ccedil;et's Disease. J Rheumatol 2001; 28:1283.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/104\" class=\"nounderline abstract_t\">Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Beh&ccedil;et's disease. Arthritis Rheum 2004; 50:2291.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/105\" class=\"nounderline abstract_t\">Bardak Y, Arido&#287;an BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Beh&ccedil;et's disease with ocular involvement. Ocul Immunol Inflamm 2004; 12:53.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/106\" class=\"nounderline abstract_t\">Suzuki N, Nara K, Suzuki T. Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behcet's disease. Clin Med Res 2006; 4:147.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/107\" class=\"nounderline abstract_t\">Imamura Y, Kurokawa MS, Yoshikawa H, et al. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol 2005; 139:371.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/108\" class=\"nounderline abstract_t\">Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bech&ccedil;et's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997; 24:128.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/109\" class=\"nounderline abstract_t\">Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades-Beh&ccedil;et's disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000; 201:37.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/110\" class=\"nounderline abstract_t\">Musabak U, Pay S, Erdem H, et al. Serum interleukin-18 levels in patients with Beh&ccedil;et's disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006; 26:545.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/111\" class=\"nounderline abstract_t\">Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Beh&ccedil;et's disease. Scand J Rheumatol 2008; 37:135.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/112\" class=\"nounderline abstract_t\">Durmazlar SP, Ulkar GB, Eskioglu F, et al. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009; 48:259.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/113\" class=\"nounderline abstract_t\">Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Beh&ccedil;et's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20:1544.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/114\" class=\"nounderline abstract_t\">Ozdamar Y, Berker N, Bahar G, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol 2009; 19:998.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/115\" class=\"nounderline abstract_t\">Akman-Demir G, T&uuml;z&uuml;n E, I&ccedil;&ouml;z S, et al. Interleukin-6 in neuro-Beh&ccedil;et's disease: association with disease subsets and long-term outcome. Cytokine 2008; 44:373.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/116\" class=\"nounderline abstract_t\">Lew W, Chang JY, Jung JY, Bang D. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Beh&ccedil;et's disease. Br J Dermatol 2008; 158:505.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/117\" class=\"nounderline abstract_t\">Pay S, Simsek I, Erdem H, et al. Dendritic cell subsets and type I interferon system in Beh&ccedil;et's disease: does functional abnormality in plasmacytoid dendritic cells contribute to Th1 polarization? Clin Exp Rheumatol 2007; 25:S34.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/118\" class=\"nounderline abstract_t\">Manta&#351; C, Direskeneli H, Ek&#351;ioglu-Demiralp E, Akoglu T. Serum levels of Th2 cytokines IL-4 and IL-10 in Beh&ccedil;et's disease. J Rheumatol 1999; 26:510.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/119\" class=\"nounderline abstract_t\">Vaccarino L, Triolo G, Accardo-Palombo A, et al. Pathological implications of Th1/Th2 cytokine genetic variants in Beh&ccedil;et's disease: Data from a pilot study in a Sicilian population. Biochem Genet 2013; 51:967.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/120\" class=\"nounderline abstract_t\">Sugita S, Kawazoe Y, Imai A, et al. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Beh&ccedil;et's disease. Arthritis Res Ther 2012; 14:R99.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/121\" class=\"nounderline abstract_t\">Shimizu J, Takai K, Fujiwara N, et al. Excessive CD4+ T cells co-expressing interleukin-17 and interferon-&gamma; in patients with Beh&ccedil;et's disease. Clin Exp Immunol 2012; 168:68.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/122\" class=\"nounderline abstract_t\">Hamzaoui K. Th17 cells in Beh&ccedil;et's disease: a new immunoregulatory axis. Clin Exp Rheumatol 2011; 29:S71.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/123\" class=\"nounderline abstract_t\">Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Beh&ccedil;et disease. J Allergy Clin Immunol 2011; 128:655.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/124\" class=\"nounderline abstract_t\">Liang L, Wang H, Peng XY, Zhao M. [The changes of Th lymphocyte subsets in patients with Behcet disease]. Zhonghua Yan Ke Za Zhi 2011; 47:393.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/125\" class=\"nounderline abstract_t\">Lee YJ, Horie Y, Wallace GR, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis 2013; 72:1510.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/126\" class=\"nounderline abstract_t\">Nanke Y, Yago T, Kotake S. The Role of Th17 Cells in the Pathogenesis of Behcet's Disease. J Clin Med 2017; 6.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/127\" class=\"nounderline abstract_t\">Deniz R, Tulunay-Virlan A, Ture Ozdemir F, et al. Th17-Inducing Conditions Lead to in vitro Activation of Both Th17 and Th1 Responses in Behcet's Disease. Immunol Invest 2017; 46:518.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/128\" class=\"nounderline abstract_t\">Kaabachi W, Bouali E, Berra&iuml;es A, et al. Interleukin-26 is overexpressed in Beh&ccedil;et's disease and enhances Th17 related -cytokines. Immunol Lett 2017; 190:177.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/129\" class=\"nounderline abstract_t\">Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Beh&ccedil;et's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999; 118:451.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/130\" class=\"nounderline abstract_t\">Yato H, Matsumoto Y. CD56+ T cells in the peripheral blood of uveitis patients. Br J Ophthalmol 1999; 83:1386.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/131\" class=\"nounderline abstract_t\">Eksioglu-Demiralp E, Direskeneli H, Ergun T, et al. Increased CD4+CD16+ and CD4+CD56+ T cell subsets in Beh&ccedil;et's disease. Rheumatol Int 1999; 19:23.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/132\" class=\"nounderline abstract_t\">Kim TW, Chung H, Yu HG. Chemokine expression of intraocular lymphocytes in patients with Beh&ccedil;et uveitis. Ophthalmic Res 2011; 45:5.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/133\" class=\"nounderline abstract_t\">Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Beh&ccedil;et's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med 2003; 141:33.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/134\" class=\"nounderline abstract_t\">Clemente A, Cambra A, Munoz-Sa&aacute; I, et al. Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Beh&ccedil;et's disease patients and healthy controls. Immunol Lett 2010; 129:57.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/135\" class=\"nounderline abstract_t\">Freysdottir J, Hussain L, Farmer I, et al. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006; 12:271.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/136\" class=\"nounderline abstract_t\">Ben Dhifallah I, Chelbi H, Braham A, et al. CTLA-4 +49A/G polymorphism is associated with Beh&ccedil;et's disease in a Tunisian population. Tissue Antigens 2009; 73:213.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/137\" class=\"nounderline abstract_t\">Yasuoka H, Okazaki Y, Kawakami Y, et al. Autoreactive CD8+ cytotoxic T lymphocytes to major histocompatibility complex class I chain-related gene A in patients with Beh&ccedil;et's disease. Arthritis Rheum 2004; 50:3658.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/138\" class=\"nounderline abstract_t\">Yu HG, Lee DS, Seo JM, et al. The number of CD8+ T cells and NKT cells increases in the aqueous humor of patients with Beh&ccedil;et's uveitis. Clin Exp Immunol 2004; 137:437.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/139\" class=\"nounderline abstract_t\">Keino H, Sakai J, Nishioka K, et al. Clonally accumulating T cells in the anterior chamber of Beh&ccedil;et disease. Am J Ophthalmol 2000; 130:243.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/140\" class=\"nounderline abstract_t\">Takase H, Sugita S, Taguchi C, et al. Capacity of ocular infiltrating T helper type 1 cells of patients with non-infectious uveitis to produce chemokines. Br J Ophthalmol 2006; 90:765.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/141\" class=\"nounderline abstract_t\">Ahn JK, Chung H, Lee DS, et al. CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis. J Immunol 2005; 175:6133.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/142\" class=\"nounderline abstract_t\">Ahn JK, Yu HG, Chung H, Park YG. Intraocular cytokine environment in active Beh&ccedil;et uveitis. Am J Ophthalmol 2006; 142:429.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/143\" class=\"nounderline abstract_t\">Guenane H, Hartani D, Chachoua L, et al. [Production of Th1/Th2 cytokines and nitric oxide in Beh&ccedil;et's uveitis and idiopathic uveitis]. J Fr Ophtalmol 2006; 29:146.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/144\" class=\"nounderline abstract_t\">Pay S, Erdem H, Pekel A, et al. Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Beh&ccedil;et's disease. Does interleukin-1beta play a major role in Beh&ccedil;et's synovitis? Rheumatol Int 2006; 26:608.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/145\" class=\"nounderline abstract_t\">Todaro M, Zerilli M, Triolo G, et al. NF-kappaB protects Beh&ccedil;et's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 2005; 52:2179.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/146\" class=\"nounderline abstract_t\">Fujimori K, Oh-i K, Takeuchi M, et al. Circulating neutrophils in Beh&ccedil;et disease is resistant for apoptotic cell death in the remission phase of uveitis. Graefes Arch Clin Exp Ophthalmol 2008; 246:285.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/147\" class=\"nounderline abstract_t\">Ozkan Y, Yardim-Akaydin S, Sepici A, et al. Assessment of homocysteine, neopterin and nitric oxide levels in Beh&ccedil;et's disease. Clin Chem Lab Med 2007; 45:73.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/148\" class=\"nounderline abstract_t\">Erturan I, Basak PY, Ozturk O, et al. Is there any relationship between serum and urine neopterin and serum interferon-gamma levels in the activity of Behcet's disease? J Eur Acad Dermatol Venereol 2009; 23:1414.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/149\" class=\"nounderline abstract_t\">Tulunay A, Dozmorov MG, Ture-Ozdemir F, et al. Activation of the JAK/STAT pathway in Behcet's disease. Genes Immun 2015; 16:170.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/150\" class=\"nounderline abstract_t\">Suh CH, Park YB, Song J, et al. Oligoclonal B lymphocyte expansion in the synovium of a patient with Beh&ccedil;et's disease. Arthritis Rheum 2001; 44:1707.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/151\" class=\"nounderline abstract_t\">Ek&#351;ioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Beh&ccedil;et's disease: increased activity in B cell subsets. J Rheumatol 1999; 26:826.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/152\" class=\"nounderline abstract_t\">Ayd&igrave;ntug AO, Tokg&ouml;z G, D'Cruz DP, et al. Antibodies to endothelial cells in patients with Beh&ccedil;et's disease. Clin Immunol Immunopathol 1993; 67:157.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/153\" class=\"nounderline abstract_t\">Direskeneli H, Keser G, D'Cruz D, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Beh&ccedil;et's disease. Clin Rheumatol 1995; 14:55.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/154\" class=\"nounderline abstract_t\">Matsui T, Kurokawa M, Kobata T, et al. Autoantibodies to T cell costimulatory molecules in systemic autoimmune diseases. J Immunol 1999; 162:4328.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/155\" class=\"nounderline abstract_t\">Matsui T, Otsuka M, Maenaka K, et al. Detection of autoantibodies to killer immunoglobulin-like receptors using recombinant fusion proteins for two killer immunoglobulin-like receptors in patients with systemic autoimmune diseases. Arthritis Rheum 2001; 44:384.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/156\" class=\"nounderline abstract_t\">Orem A, Cim&#351;it G, De&#287;er O, et al. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Beh&ccedil;et's disease. Dermatology 1999; 198:243.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/157\" class=\"nounderline abstract_t\">Feng XG, Ye S, Lu Y, et al. Antikinectin autoantibody in Beh&ccedil;et's disease and several other autoimmune connective tissue diseases. Clin Exp Rheumatol 2007; 25:S80.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/158\" class=\"nounderline abstract_t\">Choi CH, Kim TI, Kim BC, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Beh&ccedil;et's disease patients: relation to clinical course. Dis Colon Rectum 2006; 49:1849.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/159\" class=\"nounderline abstract_t\">Kurhan-Yavuz S, Direskeneli H, Bozkurt N, et al. Anti-MHC autoimmunity in Beh&ccedil;et's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis. Clin Exp Immunol 2000; 120:162.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/160\" class=\"nounderline abstract_t\">Yamamoto JH, Minami M, Inaba G, et al. Cellular autoimmunity to retinal specific antigens in patients with Beh&ccedil;et's disease. Br J Ophthalmol 1993; 77:584.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/161\" class=\"nounderline abstract_t\">de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Beh&ccedil;et's disease patients and controls. Invest Ophthalmol Vis Sci 2000; 41:3480.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/162\" class=\"nounderline abstract_t\">Zhao C, Yang P, He H, et al. S-antigen specific T helper type 1 response is present in Behcet's disease. Mol Vis 2008; 14:1456.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/163\" class=\"nounderline abstract_t\">Mahesh SP, Li Z, Buggage R, et al. Alpha tropomyosin as a self-antigen in patients with Beh&ccedil;et's disease. Clin Exp Immunol 2005; 140:368.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/164\" class=\"nounderline abstract_t\">Okunuki Y, Usui Y, Takeuchi M, et al. Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: selenium binding protein is a novel autoantigen in Behcet's disease. Exp Eye Res 2007; 84:823.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/165\" class=\"nounderline abstract_t\">Takeuchi M, Usui Y, Okunuki Y, et al. Immune responses to interphotoreceptor retinoid-binding protein and S-antigen in Behcet's patients with uveitis. Invest Ophthalmol Vis Sci 2010; 51:3067.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/166\" class=\"nounderline abstract_t\">Mor F, Weinberger A, Cohen IR. Identification of alpha-tropomyosin as a target self-antigen in Beh&ccedil;et's syndrome. Eur J Immunol 2002; 32:356.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/167\" class=\"nounderline abstract_t\">Lu Y, Ye P, Chen SL, et al. Identification of kinectin as a novel Beh&ccedil;et's disease autoantigen. Arthritis Res Ther 2005; 7:R1133.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/168\" class=\"nounderline abstract_t\">Kayik&ccedil;io&#287;lu M, Aksu K, Hasdemir C, et al. Endothelial functions in Beh&ccedil;et's disease. Rheumatol Int 2006; 26:304.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/169\" class=\"nounderline abstract_t\">Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Beh&ccedil;et's syndrome. J Am Coll Cardiol 2001; 37:517.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/170\" class=\"nounderline abstract_t\">Oflaz H, Mercanoglu F, Karaman O, et al. Impaired endothelium-dependent flow-mediated dilation in Beh&ccedil;et's disease: more prominent endothelial dysfunction in patients with vascular involvement. Int J Clin Pract 2005; 59:777.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/171\" class=\"nounderline abstract_t\">Triolo G, Accardo-Palumbo A, Triolo G, et al. Enhancement of endothelial cell E-selectin expression by sera from patients with active Beh&ccedil;et's disease: moderate correlation with anti-endothelial cell antibodies and serum myeloperoxidase levels. Clin Immunol 1999; 91:330.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/172\" class=\"nounderline abstract_t\">Kansu E, Sahin G, Sahin F, et al. Impaired prostacyclin synthesis by vessel walls in Beh&ccedil;et's disease. Lancet 1986; 2:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/173\" class=\"nounderline abstract_t\">Evereklioglu C, Turkoz Y, Er H, et al. Increased nitric oxide production in patients with Beh&ccedil;et's disease: is it a new activity marker? J Am Acad Dermatol 2002; 46:50.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/174\" class=\"nounderline abstract_t\">Evereklioglu C, Cekmen M, Ozkiri&#351; A, et al. The pathophysiological significance of red blood cell nitric oxide concentrations in inflammatory Beh&ccedil;et's disease. Mediators Inflamm 2003; 12:255.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/175\" class=\"nounderline abstract_t\">Yilmaz G, Sizmaz S, Yilmaz ED, et al. Aqueous humor nitric oxide levels in patients with Beh&ccedil;et disease. Retina 2002; 22:330.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/176\" class=\"nounderline abstract_t\">Buldanlioglu S, Turkmen S, Ayabakan HB, et al. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Beh&ccedil;et's disease. Br J Dermatol 2005; 153:526.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/177\" class=\"nounderline abstract_t\">Duygulu F, Evereklioglu C, Calis M, et al. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Beh&ccedil;et's disease: a pilot study. Clin Rheumatol 2005; 24:324.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/178\" class=\"nounderline abstract_t\">Sahin M, Arslan C, Naziroglu M, et al. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease. Ann Clin Lab Sci 2006; 36:449.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/179\" class=\"nounderline abstract_t\">Harzallah O, Kerkeni A, Baati T, Mahjoub S. Oxidative stress: correlation with Beh&ccedil;et's disease duration, activity and severity. Eur J Intern Med 2008; 19:541.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/180\" class=\"nounderline abstract_t\">Ozdemir R, Barutcu I, Sezgin AT, et al. Vascular endothelial function and plasma homocysteine levels in Behcet's disease. Am J Cardiol 2004; 94:522.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/181\" class=\"nounderline abstract_t\">Er H, Evereklioglu C, Cumurcu T, et al. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Beh&ccedil;et's disease. Br J Ophthalmol 2002; 86:653.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/182\" class=\"nounderline abstract_t\">Ate&#351; A, Aydintu&#287; O, Olmez U, et al. Serum homocysteine level is higher in Beh&ccedil;et's disease with vascular involvement. Rheumatol Int 2005; 25:42.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/183\" class=\"nounderline abstract_t\">Sarican T, Ayabakan H, Turkmen S, et al. Homocysteine: an activity marker in Beh&ccedil;et's disease? J Dermatol Sci 2007; 45:121.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/184\" class=\"nounderline abstract_t\">La Regina M, Orlandini F, Prisco D, Dentali F. Homocysteine in vascular Behcet disease: a meta-analysis. Arterioscler Thromb Vasc Biol 2010; 30:2067.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/185\" class=\"nounderline abstract_t\">Cekmen M, Evereklioglu C, Er H, et al. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Beh&ccedil;et's syndrome. Int J Dermatol 2003; 42:870.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/186\" class=\"nounderline abstract_t\">Bozoglu E, Dinc A, Erdem H, et al. Vascular endothelial growth factor and monocyte chemoattractant protein-1 in Beh&ccedil;et's patients with venous thrombosis. Clin Exp Rheumatol 2005; 23:S42.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/187\" class=\"nounderline abstract_t\">Yal&ccedil;in B, Arda N, Tezel GG, et al. Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Beh&ccedil;et's disease. Anal Quant Cytol Histol 2006; 28:303.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/188\" class=\"nounderline abstract_t\">Hamzaoui K, Ayed K, Hamza M, Hamzaoui A. VEGF and mRNA VEGF expression in CSF from Beh&ccedil;et's disease with neurological involvement. J Neuroimmunol 2009; 213:148.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/189\" class=\"nounderline abstract_t\">Nam EJ, Han SW, Kim SU, et al. Association of vascular endothelial growth factor gene polymorphisms with behcet disease in a Korean population. Hum Immunol 2005; 66:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/190\" class=\"nounderline abstract_t\">Lee KH, Chung HS, Kim HS, et al. Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Beh&ccedil;et's disease. Arthritis Rheum 2003; 48:2025.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/191\" class=\"nounderline abstract_t\">Lee JH, Cho SB, Bang D, et al. Human anti-alpha-enolase antibody in sera from patients with Beh&ccedil;et's disease and rheumatologic disorders. Clin Exp Rheumatol 2009; 27:S63.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/192\" class=\"nounderline abstract_t\">Evereklioglu C, Inal&ouml;z HS, Kirtak N, et al. Serum leptin concentration is increased in patients with Beh&ccedil;et's syndrome and is correlated with disease activity. Br J Dermatol 2002; 147:331.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/193\" class=\"nounderline abstract_t\">Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Beh&ccedil;et's disease. Am J Ophthalmol 2004; 137:850.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/194\" class=\"nounderline abstract_t\">Espinosa G, Font J, T&agrave;ssies D, et al. Vascular involvement in Beh&ccedil;et's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112:37.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/195\" class=\"nounderline abstract_t\">Haznedaro&#287;lu IC, Ozcebe O, Celik I, et al. Haemostatic markers of procoagulant imbalance in Beh&ccedil;et's disease. Eur J Haematol 1996; 57:107.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/196\" class=\"nounderline abstract_t\">Navarro S, Ricart JM, Medina P, et al. Activated protein C levels in Beh&ccedil;et's disease and risk of venous thrombosis. Br J Haematol 2004; 126:550.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/197\" class=\"nounderline abstract_t\">Akar S, Ozcan MA, Ate&#351; H, et al. Circulated activated platelets and increased platelet reactivity in patients with Beh&ccedil;et's disease. Clin Appl Thromb Hemost 2006; 12:451.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/198\" class=\"nounderline abstract_t\">Usk&uuml;dar O, Erdem A, Demiro&#287;lu H, Dikmeno&#287;lu N. Decreased erythrocyte deformability in Beh&ccedil;et's disease. Clin Hemorheol Microcirc 2005; 33:89.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/199\" class=\"nounderline abstract_t\">Tatlican S, Duran FS, Eren C, et al. Reduced erythrocyte deformability in active and untreated Beh&ccedil;et's disease patients. Int J Dermatol 2010; 49:167.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/200\" class=\"nounderline abstract_t\">Yurdakul S, Hekim N, Soysal T, et al. Fibrinolytic activity and d-dimer levels in Beh&ccedil;et's syndrome. Clin Exp Rheumatol 2005; 23:S53.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/201\" class=\"nounderline abstract_t\">Becatti M, Emmi G, Silvestri E, et al. Neutrophil Activation Promotes Fibrinogen Oxidation and Thrombus Formation in Beh&ccedil;et Disease. Circulation 2016; 133:302.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/202\" class=\"nounderline abstract_t\">Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Beh&ccedil;et's disease. Ann Rheum Dis 2004; 63:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/203\" class=\"nounderline abstract_t\">Caramaschi P, Poli G, Bonora A, et al. A study on thrombophilic factors in Italian Behcet's patients. Joint Bone Spine 2010; 77:330.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/204\" class=\"nounderline abstract_t\">Ricart JM, Ram&oacute;n LA, Vay&aacute; A, et al. Fibrinolytic inhibitor levels and polymorphisms in Beh&ccedil;et disease and their association with thrombosis. Br J Haematol 2008; 141:716.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/205\" class=\"nounderline abstract_t\">Espinosa G, Font J, T&agrave;ssies D, et al. Vascular involvement in Beh&ccedil;et's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med 2002; 112:37.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/206\" class=\"nounderline abstract_t\">Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Beh&ccedil;et's disease. Ann Rheum Dis 2004; 63:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/207\" class=\"nounderline abstract_t\">Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Beh&ccedil;et's syndrome. J Am Coll Cardiol 2001; 37:517.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/208\" class=\"nounderline abstract_t\">Alan S, Ulgen MS, Akdeniz S, et al. Intima-media thickness and arterial distensibility in Beh&ccedil;et's disease. Angiology 2004; 55:413.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/209\" class=\"nounderline abstract_t\">Itoh R, Takenaka T, Okitsu-Negishi S, et al. Interleukin 8 in Beh&ccedil;et's disease. J Dermatol 1994; 21:397.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/210\" class=\"nounderline abstract_t\">al-Dalaan A, al-Sedairy S, al-Balaa S, et al. Enhanced interleukin 8 secretion in circulation of patients with Beh&ccedil;et's disease. J Rheumatol 1995; 22:904.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/211\" class=\"nounderline abstract_t\">Ureten K, Ertenli I, Ozt&uuml;rk MA, et al. Neutrophil CD64 expression in Beh&ccedil;et's disease. J Rheumatol 2005; 32:849.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/212\" class=\"nounderline abstract_t\">Sahin S, Ako&#287;lu T, Direskeneli H, et al. Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Beh&ccedil;et's disease. Ann Rheum Dis 1996; 55:128.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/213\" class=\"nounderline abstract_t\">Saglam K, Yilmaz MI, Saglam A, et al. Levels of circulating intercellular adhesion molecule-1 in patients with Beh&ccedil;et's disease. Rheumatol Int 2002; 21:146.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/214\" class=\"nounderline abstract_t\">Ate&#351; A, Tiryaki OA, Olmez U, Tutkak H. Serum-soluble selectin levels in patients with Beh&ccedil;et's disease. Clin Rheumatol 2007; 26:411.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/215\" class=\"nounderline abstract_t\">Turkoz Y, Evereklioglu C, Ozkiri&#351; A, et al. Serum levels of soluble P-selectin are increased and associated with disease activity in patients with Beh&ccedil;et's syndrome. Mediators Inflamm 2005; 2005:237.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/216\" class=\"nounderline abstract_t\">Lee MT, Hooper LC, Kump L, et al. Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling. Clin Exp Immunol 2007; 147:71.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/217\" class=\"nounderline abstract_t\">Yamashita S, Suzuki A, Kamada M, et al. Possible physiological roles of proteolytic products of actin in neutrophils of patients with Beh&ccedil;et's disease. Biol Pharm Bull 2001; 24:733.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/218\" class=\"nounderline abstract_t\">Yamashita S, Suzuki A, Yanagita T, et al. Characterization of a protease responsible for truncated actin increase in neutrophils of patients with Beh&ccedil;et's disease. Biol Pharm Bull 2001; 24:119.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/219\" class=\"nounderline abstract_t\">Orem A, Efe H, De&#287;er O, et al. Relationship between lipid peroxidation and disease activity in patients with Beh&ccedil;et's disease. J Dermatol Sci 1997; 16:11.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/220\" class=\"nounderline abstract_t\">Yoshida T, Tanaka M, Sotomatsu A, et al. Serum of Beh&ccedil;et's disease enhances superoxide production of normal neutrophils. Free Radic Res 1998; 28:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/221\" class=\"nounderline abstract_t\">Kawakami T, Ohashi S, Kawa Y, et al. Elevated serum granulocyte colony-stimulating factor levels in patients with active phase of sweet syndrome and patients with active behcet disease: implication in neutrophil apoptosis dysfunction. Arch Dermatol 2004; 140:570.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/222\" class=\"nounderline abstract_t\">De&#287;er O, Orem A, Akyol N, et al. Polymorphonuclear leukocyte elastase levels in patients with Beh&ccedil;et's disease. Clin Chim Acta 1995; 236:129.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/223\" class=\"nounderline abstract_t\">Yazici C, K&ouml;se K, Cali&#351; M, et al. Increased advanced oxidation protein products in Beh&ccedil;et's disease: a new activity marker? Br J Dermatol 2004; 151:105.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/224\" class=\"nounderline abstract_t\">Hamzaoui K, Ma&icirc;tre B, Hamzaoui A. Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Beh&ccedil;et's disease. Clin Exp Rheumatol 2009; 27:S52.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/225\" class=\"nounderline abstract_t\">Ca&ntilde;ete JD, Celis R, Noordenbos T, et al. Distinct synovial immunopathology in Beh&ccedil;et disease and psoriatic arthritis. Arthritis Res Ther 2009; 11:R17.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/226\" class=\"nounderline abstract_t\">Sahin S, Lawrence R, Direskeneli H, et al. Monocyte activity in Beh&ccedil;et's disease. Br J Rheumatol 1996; 35:424.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/227\" class=\"nounderline abstract_t\">Neves FS, Carrasco S, Goldenstein-Schainberg C, et al. Neutrophil hyperchemotaxis in Beh&ccedil;et's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol 2009; 28:1403.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/228\" class=\"nounderline abstract_t\">Alipour S, Nouri M, Sakhinia E, et al. Epigenetic alterations in chronic disease focusing on Beh&ccedil;et's disease: Review. Biomed Pharmacother 2017; 91:526.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/229\" class=\"nounderline abstract_t\">Hughes T, Ture-Ozdemir F, Alibaz-Oner F, et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Beh&ccedil;et's disease. Arthritis Rheumatol 2014; 66:1648.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/230\" class=\"nounderline abstract_t\">Ehrlich GE. Vasculitis in Beh&ccedil;et's disease. Int Rev Immunol 1997; 14:81.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/231\" class=\"nounderline abstract_t\">Onder M, G&uuml;rer MA. Beh&ccedil;et's disease: an enigmatic vasculitis. Clin Dermatol 1999; 17:571.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/232\" class=\"nounderline abstract_t\">Kose AA. Direct immunofluorescence in Beh&ccedil;et's disease: a controlled study with 108 cases. Yonsei Med J 2009; 50:505.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/233\" class=\"nounderline abstract_t\">Inaloz HS, Evereklioglu C, Unal B, et al. The significance of immunohistochemistry in the skin pathergy reaction of patients with Beh&ccedil;et's syndrome. J Eur Acad Dermatol Venereol 2004; 18:56.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/234\" class=\"nounderline abstract_t\">Ozluk E, Balta I, Akoguz O, et al. Histopathologic Study of Pathergy Test in Beh&ccedil;et's Disease. Indian J Dermatol 2014; 59:630.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/235\" class=\"nounderline abstract_t\">Alpsoy E, Uzun S, Akman A, et al. Histological and immunofluorescence findings of non-follicular papulopustular lesions in patients with Beh&ccedil;et's disease. J Eur Acad Dermatol Venereol 2003; 17:521.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/236\" class=\"nounderline abstract_t\">Ilknur T, Pabu&ccedil;&ccedil;uoglu U, Akin C, et al. Histopathologic and direct immunofluorescence findings of the papulopustular lesions in Beh&ccedil;et's disease. Eur J Dermatol 2006; 16:146.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/237\" class=\"nounderline abstract_t\">Hatemi G, Bahar H, Uysal S, et al. The pustular skin lesions in Behcet's syndrome are not sterile. Ann Rheum Dis 2004; 63:1450.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/238\" class=\"nounderline abstract_t\">Hirohata S. Histopathology of central nervous system lesions in Beh&ccedil;et's disease. J Neurol Sci 2008; 267:41.</a></li><li><a href=\"https://www.uptodate.com/contents/pathogenesis-of-behcet-syndrome/abstract/239\" class=\"nounderline abstract_t\">Ardalan MR, Sadreddini S, Noshad H, et al. Renal involvement in Behcet's disease. Saudi J Kidney Dis Transpl 2009; 20:618.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8233 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H17358645\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETIOLOGY AND PATHOGENESIS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Genetic</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- HLA genes</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Non-HLA genes</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">Altered bacteria and bacteria response</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Altered innate immune function</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Cellular immunity and cytokines</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Autoantibody and immune complex formation</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Endothelial activation and altered coagulation</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Neutrophil activation</a></li><li><a href=\"#H2522010038\" id=\"outline-link-H2522010038\">Epigenetic alterations</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">PATHOLOGY</a></li><li><a href=\"#H4084931802\" id=\"outline-link-H4084931802\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H17358645\" id=\"outline-link-H17358645\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-behcet-syndrome\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Beh&ccedil;et syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">Overview of hemostasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-vasculitis\" class=\"medical medical_society_guidelines\">Society guideline links: Vasculitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-behcet-syndrome\" class=\"medical medical_review\">Treatment of Beh&ccedil;et syndrome</a></li></ul></div></div>","javascript":null}